<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471497</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107A2303</org_study_id>
    <secondary_id>2007-000208-34</secondary_id>
    <nct_id>NCT00471497</nct_id>
    <nct_alias>NCT00718263</nct_alias>
  </id_info>
  <brief_title>A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)</brief_title>
  <acronym>ENESTnd</acronym>
  <official_title>A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg&#xD;
      twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with&#xD;
      Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase&#xD;
      (CML-CP).&#xD;
&#xD;
      An extension protocol was included in this study design to allow patients who did not show&#xD;
      sufficient response to their assigned treatments the opportunity to receive imatinib 400 mg&#xD;
      BID (option available until protocol amendment 7) or nilotinib 400 mg BID, using an&#xD;
      abbreviated safety and efficacy assessment schedule.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives of this study:&#xD;
&#xD;
        -  Compared the efficacy (major molecular response (MMR) rate at 12 months) of nilotinib at&#xD;
           400 mg bid with that of imatinib 400 mg qd in newly diagnosed, previously untreated Ph+&#xD;
           CML-CP patients.&#xD;
&#xD;
        -  Compared the efficacy (MMR rate at 12 months) of nilotinib at 300 mg bid with that of&#xD;
           imatinib 400 mg qd in newly diagnosed, previously untreated Ph+ CML-CP patients.&#xD;
&#xD;
      The Primary objectives of Extension Phase of the study:&#xD;
&#xD;
      - Characterized the safety and tolerability profile of nilotinib 400 mg BID after failure of&#xD;
      imatinib or insufficiently responded to nilotinib 300 mg BID therapy and the safety and&#xD;
      tolerability profile of imatinib therapy after failure of nilotinib therapy.&#xD;
&#xD;
      The study was designed to determine whether the treatment of newly diagnosed, previously&#xD;
      untreated Ph+ CML-CP patients with either nilotinib 300 mg bid or 400 mg bid demonstrated&#xD;
      improved efficacy compared to imatinib 400 mg qd. The primary efficacy endpoint was the rate&#xD;
      of MMR defined as the proportion of patients who achieved ≥ 3 log reduction in BCR-ABL&#xD;
      transcripts compared to either the standardized Baseline established in the IRIS trial&#xD;
      (International Randomized Interferon versus STI571) (Cortes et al 2005) or to the BCR-ABL&#xD;
      ratio ≤ 0.1% by International Scale, as detected by real-time quantitative polymerase chain&#xD;
      reaction (RQ-PCR) at 12 months.&#xD;
&#xD;
      The key secondary endpoint was to compare the rate of durable MMR between nilotinib 300 mg&#xD;
      bid with that of imatinib, and of nilotinib 400 mg bid with that of imatinib at 24 months.&#xD;
      This report presents the final results of efficacy and safety at the LPLV (21-Aug-2019).&#xD;
&#xD;
      The main data analysis was done at the time when all patients completed 12 cycles of&#xD;
      treatment (or discontinued earlier). There were two primary comparisons at this time point:&#xD;
      the MMR rate of nilotinib 400 mg versus the MMR rate of imatinib 400 mg, and the MMR rate of&#xD;
      the nilotinib 300 mg versus the MMR rate of the imatinib 400 mg. Comparisons were done&#xD;
      sequentially, i.e. the MMR rate of nilotinib 400 mg versus the MMR rate of imatinib 400 mg&#xD;
      was to be compared first; if it was significant at 5% level, the MMR rate of the nilotinib&#xD;
      300 mg versus the MMR rate of the imatinib 400 mg was to be compared. The study had a 90%&#xD;
      power to detect a 15% difference between the nilotinib 400 mg arm versus imatinib 400 mg arm&#xD;
      assuming that the MMR rate of imatinib is 40% and the MMR rate of nilotinib is 55%. The study&#xD;
      also had a 90% power to detect a 15% difference between the nilotinib 300 mg and the imatinib&#xD;
      400 mg arms, if the comparison between the nilotinib 400 mg and the imatinib 400 mg was&#xD;
      significant.&#xD;
&#xD;
      The second main data analysis was done at the time when all patients completed 24 cycles of&#xD;
      treatment (or discontinued earlier). There were two key comparisons at this time point: the&#xD;
      rate of durable MMR at 24 months of the nilotinib 400 mg versus the imatinib 400 mg, and the&#xD;
      rate of durable MMR at 24 months of the nilotinib 300 mg versus the imatinib 400 mg.&#xD;
&#xD;
      In order to control the overall type I error rate at or below 5%, only when the corresponding&#xD;
      comparison on the primary efficacy endpoint(s) was (were) significant, the key secondary&#xD;
      comparison(s) of the respective nilotinib doses (400 mg bid and/or 300 mg bid) versus&#xD;
      imatinib 400 mg qd were tested at two-sided 5% significance level.&#xD;
&#xD;
      Patients participating after demonstrating suboptimal response/treatment failure to their&#xD;
      assigned study treatment in the core study were offered the option to continue in the&#xD;
      extension study and to receive imatinib 400 mg bid (option available only until protocol&#xD;
      amendment 7) or nilotinib therapy at a dose of 400 mg bid.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2007</start_date>
  <completion_date type="Actual">August 21, 2019</completion_date>
  <primary_completion_date type="Actual">September 2, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With Imputation</measure>
    <time_frame>12 months</time_frame>
    <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of Durable MMR at 24 Months Between All 3 Arms</measure>
    <time_frame>24 months</time_frame>
    <description>Durable MMR at 24 months is defined as having MMR both at 12 months and at 24 months, and with no documented loss of MMR between these 12 month and 24 month time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months and Beyond 12 Months</measure>
    <time_frame>12, 24, 36, 48, 60, 72 months (M)</time_frame>
    <description>CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Patients with no CCyR as the best response by any specific time point, all missing cytogenetic evaluations by that time point or Ph- at baseline are combined as &quot;Nocomplete cytogenetic response&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms</measure>
    <time_frame>12 months</time_frame>
    <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months based on 12-month cut-off interim data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MMR at 6 Months and Beyond in All 3 Treatment Arms</measure>
    <time_frame>6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months</time_frame>
    <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 6 months and beyond up to 120 months based on final data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib</measure>
    <time_frame>at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months</time_frame>
    <description>Molecular response of &lt;=0.01% is defined as BCR-ABL ratio (%) on IS &lt;= 0.01% (corresponds to &gt;=4 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of a ≥ 4.5 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib</measure>
    <time_frame>at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months</time_frame>
    <description>This is the molecular response of &lt;=0.0032% is defined as BCR-ABL ratio (%) on IS &lt;= 0.0032% (corresponds to &gt;=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First MMR</measure>
    <time_frame>up to 84 months</time_frame>
    <description>Time to MMR is defined as time from date of randomization to the date of the first documented MMR in nilotinib treatment arms, compared to imatinib in adult patients with Ph+ CML in CP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of MMR</measure>
    <time_frame>approx. 11 years</time_frame>
    <description>Duration of MMR for patients with MMR is defined as the time between date of MMR and the earliest of the following: loss of MMR, CML-related death or progression to AP/BC during study treatment The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts</measure>
    <time_frame>up to 84 months</time_frame>
    <description>Time to BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% is defined as: date of first BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% - date of randomization +1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts</measure>
    <time_frame>approx. 11 years</time_frame>
    <description>It is defined as the time from the date of first documented BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% to the earliest of the following: Loss of BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032%, respectively, CML-related death or progression to AP/BC during study treatment. The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hematologic Response</measure>
    <time_frame>12 months, 24 months, Overall on Core study (approx. 11 years)</time_frame>
    <description>Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count &lt;10 x 109/L, Platelet count &lt;450 x 109/L, Basophils &lt;5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes &lt; 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Cytogenic Response (CCyR)</measure>
    <time_frame>24 months</time_frame>
    <description>Time to CCyR is defined as the time from the date of randomization to the date of first documented CCyR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CCyR</measure>
    <time_frame>up to 72 months</time_frame>
    <description>Duration of CCyR is defined as the time from date of first documented CCyR to the earliest date of loss of CCyR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>approx. 11 years</time_frame>
    <description>Progression-free survival is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring in the core or extension study, or during the follow-up period after discontinuation of core or extension study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>approx. 11 years</time_frame>
    <description>Event-free survival is defined as the time from the date of randomization to the date of first occurrence of any of the following: death due to any cause (if death is the primary reason for discontinuation), progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>approx. 11 years</time_frame>
    <description>OS is defined as the time from the date of randomization to the date death. Up to 10 calendar years of follow up from the date when the last patient randomized received the first dose of study drug in all active treatment arms of adult patients with Ph+ CML CP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Dose-intensity</measure>
    <time_frame>approx. 11 years</time_frame>
    <description>Actual dose intensity is defined as total dose over time on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression to AP/BC</measure>
    <time_frame>approx. 11 years</time_frame>
    <description>Time to progression to AP/BC is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of CML related death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration</time_frame>
    <description>Cmax is defined as the maximum serum concentration after dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmin</measure>
    <time_frame>any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration</time_frame>
    <description>Cmin is defined as the minimum serum concentration after dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax</measure>
    <time_frame>any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration</time_frame>
    <description>Tmax is defined as the sampling time when maximum measured serum concentration occurs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC0-last</measure>
    <time_frame>any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration</time_frame>
    <description>AUC0-last is defined as area under concentration-time curve from time zero to the last measurable sample, calculated by log-linear trapezoidal method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</measure>
    <time_frame>Overall for Extension study for approx. 10 years</time_frame>
    <description>Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count &lt;10 x 109/L, Platelet count &lt;450 x 109/L, Basophils &lt;5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes &lt; 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</measure>
    <time_frame>Overall for Extension study for approx. 10 years</time_frame>
    <description>Rate of CCyR is defined as the percentage of participants in complete cytogenetic response (CCyR). CcyR is defined as 0% of Ph+ metaphases in the bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</measure>
    <time_frame>Overall for Extension study for approx. 10 years</time_frame>
    <description>Rate of MMR is defined as the percentage pf participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</measure>
    <time_frame>Overall for Extension study for approx. 10 years</time_frame>
    <description>Molecular response of &lt;=0.01% is defined as BCR-ABL ratio (%) on IS &lt;= 0.01% (corresponds to &gt;=4 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</measure>
    <time_frame>Overall for Extension study for approx. 10 years</time_frame>
    <description>Molecular response of &lt;=0.0032% is defined as BCR-ABL ratio (%) on IS &lt;= 0.0032% (corresponds to &gt;=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension)</measure>
    <time_frame>Overall for Extension study for approx. 10 years</time_frame>
    <description>This is the percentage of patients with any emergent mutation on extension treatment. The mutation comprised of T315T, less sensitive to nilotinib, unknown and sensitive to nilotinib.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">846</enrollment>
  <condition>Myelogenous Leukemia, Chronic</condition>
  <arm_group>
    <arm_group_label>nilotinib 300mg bid (investigating arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nilotinb 400 mg bid (investigating arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>imatinib 400mg QD (control arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <description>Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.</description>
    <arm_group_label>Nilotinb 400 mg bid (investigating arm)</arm_group_label>
    <arm_group_label>nilotinib 300mg bid (investigating arm)</arm_group_label>
    <other_name>AMN107</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib</intervention_name>
    <description>Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).</description>
    <arm_group_label>imatinib 400mg QD (control arm)</arm_group_label>
    <other_name>STI571</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion criteria:&#xD;
&#xD;
          -  Chronic myelogenous leukemia in chronic phase patients within the first 6 months of&#xD;
             diagnosis.&#xD;
&#xD;
          -  Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of&#xD;
             Philadelphia chromosome of (9:22) translocations&#xD;
&#xD;
        Key Exclusion criteria:&#xD;
&#xD;
          -  Previously documented T315I mutation&#xD;
&#xD;
          -  Treatment with a tyrosine kinase inhibitor prior to study entry is not allowed except&#xD;
             for no more than 2 weeks in duration of imatinib&#xD;
&#xD;
          -  Any medical treatment for CML prior to study entry for longer than 2 weeks with the&#xD;
             exception of hydroxyurea and/or anagrelide&#xD;
&#xD;
          -  Impaired cardiac function.&#xD;
&#xD;
          -  Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or&#xD;
             uncontrolled infection).&#xD;
&#xD;
          -  Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)&#xD;
&#xD;
          -  Currently receiving treatment with any medications that have the potential to prolong&#xD;
             the QT interval.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles Dept. of Hematology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - California Southern Dept of Kaiser South 3</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - California Northern Vallejo Med Center/Med Offices</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - California Northern Kaiser Med</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers RMCC - Colorado Springs</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists Dept. FloridaCancerSpecialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Specialties Research Dept.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Florida PA Cancer Centers of FL</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Retina Institute Flordia Cancer Affilates</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Section of Hematology/Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Institute Dept. of Indiana Blood&amp;Marrow</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics Dept.of U of Iowa Hosp&amp;Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Center KCCC Business Office</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University / Breslin Cancer Center Breslin Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Cancer Associates Dept. of Boone Hospital Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Consultants, Inc. Deptof Hem. Onc.Consunsultants</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Department of Research</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Clinical Trials Office</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina UNC Lineberger Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences Dept. of Industry Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati / Barrett Cancer Center Dept.of Internal Med.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation CCF</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists Compass Oncology -BKM</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas CC of C -Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology Dept. of Centennial Medical</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center ( Medical City Dallas Hospital)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas HOAST CCC of So.TX- Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1902AVG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70330-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jau</city>
        <state>SP</state>
        <zip>17210-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01224-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01401-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>110111</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <zip>110001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <state>Czech Republic</state>
        <zip>128 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <state>CZE</state>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HUS Helsinki</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <state>Cedex 10</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caen</city>
        <state>Cedex</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <state>Loire</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Angers Cedex 1</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes</city>
        <zip>35019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68305</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eisenach</city>
        <zip>99817</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>453-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466 8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi city</city>
        <state>Gunma</state>
        <zip>371 8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-0821</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo city</city>
        <state>Hokkaido</state>
        <zip>060 8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663 8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tsukuba city</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanazawa-city</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto City</city>
        <state>Kumamoto</state>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tsu-city</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagasaki-city</city>
        <state>Nagasaki</state>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka Sayama</city>
        <state>Osaka</state>
        <zip>589 8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita city</city>
        <state>Osaka</state>
        <zip>565 0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hidaka-city</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamamatsu-city</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo ku</city>
        <state>Tokyo</state>
        <zip>113 8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104 0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa ku</city>
        <state>Tokyo</state>
        <zip>141 8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160 8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Akita</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiba</city>
        <zip>260 8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niigata</city>
        <zip>951 8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saitama</city>
        <zip>330 8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seocho Gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>519763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Selangor</city>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40032</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35 055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <state>Slovak Republic</state>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>85107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0027</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bilbao</city>
        <state>Pais Vasco</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Sebastian</city>
        <state>Pais Vasco</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huddinge</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lulea</city>
        <zip>SE 971 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orebro</city>
        <zip>SE-701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sundsvall</city>
        <zip>SE-851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <state>TUR</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <state>Distrito Capital</state>
        <zip>1010</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
    <country>Czech Republic</country>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <results_first_submitted>April 10, 2013</results_first_submitted>
  <results_first_submitted_qc>June 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2013</results_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>bone marrow</keyword>
  <keyword>leukemia symptoms</keyword>
  <keyword>lukemia</keyword>
  <keyword>cml</keyword>
  <keyword>complete blood count</keyword>
  <keyword>lymphocyte</keyword>
  <keyword>blood cancer</keyword>
  <keyword>leukocytes</keyword>
  <keyword>chronic leukemia</keyword>
  <keyword>bone marrow biopsy</keyword>
  <keyword>leukemia research</keyword>
  <keyword>leukemia cells</keyword>
  <keyword>bone marrow disease</keyword>
  <keyword>chronic myeloid leukemia</keyword>
  <keyword>blood cancer symptoms</keyword>
  <keyword>white blood cell diseases</keyword>
  <keyword>chronic myelogenous leukemia</keyword>
  <keyword>leukemia treatment</keyword>
  <keyword>leukemia facts</keyword>
  <keyword>leucemia</keyword>
  <keyword>facts about leukemia</keyword>
  <keyword>myelogenous leukemia</keyword>
  <keyword>newly diagnosed CML</keyword>
  <keyword>newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study over-enrolled, and 846 patients (283 in the imatinib 400 mg arm, 282 in the nilotinib 300 mg arm and 281 in the nilotinib 400 mg arm) were randomized. DP = disease progression, SOR/TF = Suboptimal response or treatment failure</recruitment_details>
      <pre_assignment_details>Randomization was planned for a total of 771 patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Imatinib 400 mg QD</title>
          <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
        </group>
        <group group_id="P2">
          <title>Nilotinb 300 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
        <group group_id="P3">
          <title>Nilotinib 400 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="283"/>
                <participants group_id="P2" count="282"/>
                <participants group_id="P3" count="281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="280">Safety set contained patients who received at least one dose of study medication.</participants>
                <participants group_id="P2" count="279">Safety set contained patients who received at least one dose of study medication.</participants>
                <participants group_id="P3" count="277">Safety set contained patients who received at least one dose of study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discon. Core/Did Not Enter Ext.</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="256"/>
                <participants group_id="P3" count="278"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Core/Entered Ext.</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="175"/>
                <participants group_id="P3" count="182"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Abnormal Laboratory Values</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Test Procedures</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sub optimal response or treat. failure</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disc. Core/Entered Ext. - DP progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disc. Core/Entered Ext.- SOR/TF</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
      <group_list>
        <group group_id="B1">
          <title>Imatinib 400 mg QD</title>
          <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
        </group>
        <group group_id="B2">
          <title>Nilotinb 300 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
        <group group_id="B3">
          <title>Nilotinib 400 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="283"/>
            <count group_id="B2" value="282"/>
            <count group_id="B3" value="281"/>
            <count group_id="B4" value="846"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;35 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 35 - &lt;45 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=45 - &lt;55 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=55 - &lt; 65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="355"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Missing patient that cannot be identified</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="282"/>
                    <count group_id="B2" value="281"/>
                    <count group_id="B3" value="280"/>
                    <count group_id="B4" value="843"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation</title>
        <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation</title>
          <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" lower_limit="17.6" upper_limit="27.6"/>
                    <measurement group_id="O2" value="44.3" lower_limit="38.4" upper_limit="50.3"/>
                    <measurement group_id="O3" value="42.7" lower_limit="36.8" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rate</param_type>
            <param_value>22.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.5</ci_lower_limit>
            <ci_upper_limit>29.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rate</param_type>
            <param_value>20.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.9</ci_lower_limit>
            <ci_upper_limit>28.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With Imputation</title>
        <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With Imputation</title>
          <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sokal risk group = Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" lower_limit="17.9" upper_limit="35.5"/>
                    <measurement group_id="O2" value="40.8" lower_limit="31.2" upper_limit="50.9"/>
                    <measurement group_id="O3" value="53.4" lower_limit="43.3" upper_limit="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sokal risk group = Interm.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" lower_limit="15.0" upper_limit="32.2"/>
                    <measurement group_id="O2" value="50.5" lower_limit="40.4" upper_limit="60.6"/>
                    <measurement group_id="O3" value="40.0" lower_limit="30.3" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sokal risk group = High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="9.2" upper_limit="26.8"/>
                    <measurement group_id="O2" value="41.0" lower_limit="30.0" upper_limit="52.7"/>
                    <measurement group_id="O3" value="32.1" lower_limit="21.9" upper_limit="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>(Low)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in response rate</param_type>
            <param_value>14.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>27.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>(Low)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in response rate</param_type>
            <param_value>27.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.6</ci_lower_limit>
            <ci_upper_limit>40.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>(Intermediate)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in response rate</param_type>
            <param_value>27.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.0</ci_lower_limit>
            <ci_upper_limit>40.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>(Intermediate)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in response rate</param_type>
            <param_value>17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
            <ci_upper_limit>29.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>(High)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in response rate</param_type>
            <param_value>24.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.7</ci_lower_limit>
            <ci_upper_limit>38.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>(High)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in response rate</param_type>
            <param_value>15.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>28.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Durable MMR at 24 Months Between All 3 Arms</title>
        <description>Durable MMR at 24 months is defined as having MMR both at 12 months and at 24 months, and with no documented loss of MMR between these 12 month and 24 month time points.</description>
        <time_frame>24 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Durable MMR at 24 Months Between All 3 Arms</title>
          <description>Durable MMR at 24 months is defined as having MMR both at 12 months and at 24 months, and with no documented loss of MMR between these 12 month and 24 month time points.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="15.9" upper_limit="25.7"/>
                    <measurement group_id="O2" value="41.8" lower_limit="36.0" upper_limit="47.8"/>
                    <measurement group_id="O3" value="39.1" lower_limit="33.4" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in response rate</param_type>
            <param_value>21.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.9</ci_lower_limit>
            <ci_upper_limit>28.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in response rate</param_type>
            <param_value>18.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.3</ci_lower_limit>
            <ci_upper_limit>26.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months and Beyond 12 Months</title>
        <description>CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Patients with no CCyR as the best response by any specific time point, all missing cytogenetic evaluations by that time point or Ph- at baseline are combined as &quot;Nocomplete cytogenetic response&quot;.</description>
        <time_frame>12, 24, 36, 48, 60, 72 months (M)</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months and Beyond 12 Months</title>
          <description>CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Patients with no CCyR as the best response by any specific time point, all missing cytogenetic evaluations by that time point or Ph- at baseline are combined as &quot;Nocomplete cytogenetic response&quot;.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CCyR at M12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5"/>
                    <measurement group_id="O2" value="70.2"/>
                    <measurement group_id="O3" value="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCyR at M24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="66.0"/>
                    <measurement group_id="O3" value="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCyR at M36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCyR at M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCyR at M60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCyR at M72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms</title>
        <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months based on 12-month cut-off interim data.</description>
        <time_frame>12 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O2">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms</title>
          <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months based on 12-month cut-off interim data.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" lower_limit="38.4" upper_limit="50.3"/>
                    <measurement group_id="O2" value="42.7" lower_limit="36.8" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6987</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Absolute difference</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of MMR at 6 Months and Beyond in All 3 Treatment Arms</title>
        <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 6 months and beyond up to 120 months based on final data.</description>
        <time_frame>6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of MMR at 6 Months and Beyond in All 3 Treatment Arms</title>
          <description>MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 6 months and beyond up to 120 months based on final data.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMR at M6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="8.5" upper_limit="16.4"/>
                    <measurement group_id="O2" value="33.0" lower_limit="27.5" upper_limit="38.8"/>
                    <measurement group_id="O3" value="29.5" lower_limit="24.3" upper_limit="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR at M12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" lower_limit="17.6" upper_limit="27.6"/>
                    <measurement group_id="O2" value="44.7" lower_limit="38.8" upper_limit="50.7"/>
                    <measurement group_id="O3" value="43.1" lower_limit="37.2" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR at M24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="31.8" upper_limit="43.4"/>
                    <measurement group_id="O2" value="61.7" lower_limit="55.8" upper_limit="67.4"/>
                    <measurement group_id="O3" value="59.1" lower_limit="53.1" upper_limit="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR at M36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="32.8" upper_limit="44.5"/>
                    <measurement group_id="O2" value="59.2" lower_limit="53.2" upper_limit="65.0"/>
                    <measurement group_id="O3" value="57.3" lower_limit="51.3" upper_limit="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR at M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" lower_limit="38.0" upper_limit="49.8"/>
                    <measurement group_id="O2" value="59.9" lower_limit="54.0" upper_limit="65.7"/>
                    <measurement group_id="O3" value="55.2" lower_limit="49.1" upper_limit="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR at M60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" lower_limit="43.2" upper_limit="55.1"/>
                    <measurement group_id="O2" value="62.8" lower_limit="56.8" upper_limit="68.4"/>
                    <measurement group_id="O3" value="61.2" lower_limit="55.2" upper_limit="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR at M72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="35.9" upper_limit="47.7"/>
                    <measurement group_id="O2" value="52.5" lower_limit="46.5" upper_limit="58.4"/>
                    <measurement group_id="O3" value="57.7" lower_limit="51.6" upper_limit="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR at M84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" lower_limit="34.5" upper_limit="46.3"/>
                    <measurement group_id="O2" value="50.0" lower_limit="44.0" upper_limit="56.0"/>
                    <measurement group_id="O3" value="50.9" lower_limit="44.9" upper_limit="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR at M96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="31.8" upper_limit="43.4"/>
                    <measurement group_id="O2" value="46.1" lower_limit="40.2" upper_limit="52.1"/>
                    <measurement group_id="O3" value="46.3" lower_limit="40.3" upper_limit="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR at M108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="31.8" upper_limit="43.4"/>
                    <measurement group_id="O2" value="43.3" lower_limit="37.4" upper_limit="49.3"/>
                    <measurement group_id="O3" value="40.2" lower_limit="34.4" upper_limit="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMR at M120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="30.8" upper_limit="42.3"/>
                    <measurement group_id="O2" value="37.9" lower_limit="32.3" upper_limit="43.9"/>
                    <measurement group_id="O3" value="39.1" lower_limit="33.4" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib</title>
        <description>Molecular response of &lt;=0.01% is defined as BCR-ABL ratio (%) on IS &lt;= 0.01% (corresponds to &gt;=4 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
        <time_frame>at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib</title>
          <description>Molecular response of &lt;=0.01% is defined as BCR-ABL ratio (%) on IS &lt;= 0.01% (corresponds to &gt;=4 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Molecular response of &lt;=0.01% at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.2" upper_limit="3.1"/>
                    <measurement group_id="O2" value="8.9" lower_limit="5.8" upper_limit="12.8"/>
                    <measurement group_id="O3" value="5.7" lower_limit="3.3" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.0" upper_limit="6.8"/>
                    <measurement group_id="O2" value="12.1" lower_limit="8.5" upper_limit="16.4"/>
                    <measurement group_id="O3" value="8.9" lower_limit="5.8" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="7.0" upper_limit="14.4"/>
                    <measurement group_id="O2" value="24.5" lower_limit="19.6" upper_limit="29.9"/>
                    <measurement group_id="O3" value="22.1" lower_limit="17.4" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="10.3" upper_limit="18.7"/>
                    <measurement group_id="O2" value="29.4" lower_limit="24.2" upper_limit="35.1"/>
                    <measurement group_id="O3" value="23.8" lower_limit="19.0" upper_limit="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 48 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="15.3" upper_limit="24.9"/>
                    <measurement group_id="O2" value="33.0" lower_limit="27.5" upper_limit="38.8"/>
                    <measurement group_id="O3" value="29.9" lower_limit="24.6" upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="25.7" upper_limit="36.8"/>
                    <measurement group_id="O2" value="47.9" lower_limit="41.9" upper_limit="53.9"/>
                    <measurement group_id="O3" value="43.4" lower_limit="37.5" upper_limit="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 72 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" lower_limit="22.1" upper_limit="32.8"/>
                    <measurement group_id="O2" value="44.3" lower_limit="38.4" upper_limit="50.3"/>
                    <measurement group_id="O3" value="45.2" lower_limit="39.3" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 84 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="23.8" upper_limit="34.6"/>
                    <measurement group_id="O2" value="42.9" lower_limit="37.1" upper_limit="48.9"/>
                    <measurement group_id="O3" value="40.6" lower_limit="34.8" upper_limit="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 96 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" lower_limit="23.1" upper_limit="33.9"/>
                    <measurement group_id="O2" value="39.7" lower_limit="34.0" upper_limit="45.7"/>
                    <measurement group_id="O3" value="38.1" lower_limit="32.4" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 108 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" lower_limit="26.7" upper_limit="37.9"/>
                    <measurement group_id="O2" value="40.4" lower_limit="34.6" upper_limit="46.4"/>
                    <measurement group_id="O3" value="34.9" lower_limit="29.3" upper_limit="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 120 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" lower_limit="23.1" upper_limit="33.9"/>
                    <measurement group_id="O2" value="35.5" lower_limit="29.9" upper_limit="41.4"/>
                    <measurement group_id="O3" value="33.8" lower_limit="28.3" upper_limit="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of a ≥ 4.5 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib</title>
        <description>This is the molecular response of &lt;=0.0032% is defined as BCR-ABL ratio (%) on IS &lt;= 0.0032% (corresponds to &gt;=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
        <time_frame>at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of a ≥ 4.5 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib</title>
          <description>This is the molecular response of &lt;=0.0032% is defined as BCR-ABL ratio (%) on IS &lt;= 0.0032% (corresponds to &gt;=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Molecular response of &lt;=0.0032% at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.7" upper_limit="6.4"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.4" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.0032% at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="4.6" lower_limit="2.5" upper_limit="7.8"/>
                    <measurement group_id="O3" value="5.0" lower_limit="2.8" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.0032% at 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.2" upper_limit="5.5"/>
                    <measurement group_id="O2" value="12.4" lower_limit="8.8" upper_limit="16.8"/>
                    <measurement group_id="O3" value="7.8" lower_limit="5.0" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.0032% at 36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="5.2" upper_limit="11.9"/>
                    <measurement group_id="O2" value="13.8" lower_limit="10.0" upper_limit="18.4"/>
                    <measurement group_id="O3" value="12.1" lower_limit="8.5" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01032 at 48 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="7.0" upper_limit="14.4"/>
                    <measurement group_id="O2" value="16.3" lower_limit="12.2" upper_limit="21.2"/>
                    <measurement group_id="O3" value="17.1" lower_limit="12.9" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.0032% at 60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="15.3" upper_limit="24.9"/>
                    <measurement group_id="O2" value="32.3" lower_limit="26.8" upper_limit="38.1"/>
                    <measurement group_id="O3" value="29.5" lower_limit="24.3" upper_limit="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.0032% at 72 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="13.7" upper_limit="23.0"/>
                    <measurement group_id="O2" value="31.2" lower_limit="25.8" upper_limit="37.0"/>
                    <measurement group_id="O3" value="28.8" lower_limit="23.6" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.0032% at 84 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="14.7" upper_limit="24.2"/>
                    <measurement group_id="O2" value="31.6" lower_limit="26.2" upper_limit="37.3"/>
                    <measurement group_id="O3" value="28.8" lower_limit="23.6" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.01% at 96 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="18.5" upper_limit="28.7"/>
                    <measurement group_id="O2" value="31.9" lower_limit="26.5" upper_limit="37.7"/>
                    <measurement group_id="O3" value="32.4" lower_limit="26.9" upper_limit="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.0032% at 108 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="19.2" upper_limit="29.4"/>
                    <measurement group_id="O2" value="31.9" lower_limit="26.5" upper_limit="37.7"/>
                    <measurement group_id="O3" value="28.1" lower_limit="22.9" upper_limit="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular response of &lt;=0.0032% at 120 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="16.6" upper_limit="26.4"/>
                    <measurement group_id="O2" value="27.0" lower_limit="21.9" upper_limit="32.5"/>
                    <measurement group_id="O3" value="25.6" lower_limit="20.6" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First MMR</title>
        <description>Time to MMR is defined as time from date of randomization to the date of the first documented MMR in nilotinib treatment arms, compared to imatinib in adult patients with Ph+ CML in CP.</description>
        <time_frame>up to 84 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First MMR</title>
          <description>Time to MMR is defined as time from date of randomization to the date of the first documented MMR in nilotinib treatment arms, compared to imatinib in adult patients with Ph+ CML in CP.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.13" lower_limit="11.60" upper_limit="17.31"/>
                    <measurement group_id="O2" value="8.31" lower_limit="6.21" upper_limit="8.48"/>
                    <measurement group_id="O3" value="8.53" lower_limit="8.31" upper_limit="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of MMR</title>
        <description>Duration of MMR for patients with MMR is defined as the time between date of MMR and the earliest of the following: loss of MMR, CML-related death or progression to AP/BC during study treatment The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.</description>
        <time_frame>approx. 11 years</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of MMR</title>
          <description>Duration of MMR for patients with MMR is defined as the time between date of MMR and the earliest of the following: loss of MMR, CML-related death or progression to AP/BC during study treatment The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of duration MMR</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of duration MMR</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of duration MMR</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts</title>
        <description>Time to BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% is defined as: date of first BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% - date of randomization +1.</description>
        <time_frame>up to 84 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts</title>
          <description>Time to BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% is defined as: date of first BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% - date of randomization +1.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>time to first molecular response of &lt;=0.01%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.46" lower_limit="24.11" upper_limit="36.01"/>
                    <measurement group_id="O2" value="19.38" lower_limit="16.62" upper_limit="22.34"/>
                    <measurement group_id="O3" value="22.70" lower_limit="19.48" upper_limit="27.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>time to first molecular response of &lt;=0.0032%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.29" lower_limit="33.45" upper_limit="41.63"/>
                    <measurement group_id="O2" value="32.46" lower_limit="23.23" upper_limit="38.67"/>
                    <measurement group_id="O3" value="35.94" lower_limit="30.39" upper_limit="41.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts</title>
        <description>It is defined as the time from the date of first documented BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% to the earliest of the following: Loss of BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032%, respectively, CML-related death or progression to AP/BC during study treatment. The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.</description>
        <time_frame>approx. 11 years</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts</title>
          <description>It is defined as the time from the date of first documented BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% to the earliest of the following: Loss of BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032%, respectively, CML-related death or progression to AP/BC during study treatment. The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>duration of first molecular response of &lt;=0.01%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of this molecular response (BCR-ABL ratio of ≤ 0.01%)</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of this molecular response (BCR-ABL ratio of ≤ 0.01%)</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of this molecular response (BCR-ABL ratio of ≤ 0.01%)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>duration of first molecular response of &lt;=0.0032%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of this molecular response (BCR-ABL ratio of ≤ 0.0032%)</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of this molecular response (BCR-ABL ratio of ≤ 0.0032%)</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of this molecular response (BCR-ABL ratio of ≤ 0.0032%)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Hematologic Response</title>
        <description>Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count &lt;10 x 109/L, Platelet count &lt;450 x 109/L, Basophils &lt;5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes &lt; 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).</description>
        <time_frame>12 months, 24 months, Overall on Core study (approx. 11 years)</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Hematologic Response</title>
          <description>Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count &lt;10 x 109/L, Platelet count &lt;450 x 109/L, Basophils &lt;5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes &lt; 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete hematologic response (CHR) by M12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="89.7" upper_limit="95.9"/>
                    <measurement group_id="O2" value="90.1" lower_limit="86.0" upper_limit="93.3"/>
                    <measurement group_id="O3" value="89.0" lower_limit="84.7" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHR by M24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6" lower_limit="90.1" upper_limit="96.2"/>
                    <measurement group_id="O2" value="90.8" lower_limit="86.8" upper_limit="93.9"/>
                    <measurement group_id="O3" value="90.4" lower_limit="86.3" upper_limit="93.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHR Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" lower_limit="90.6" upper_limit="96.5"/>
                    <measurement group_id="O2" value="92.2" lower_limit="88.4" upper_limit="95.0"/>
                    <measurement group_id="O3" value="90.7" lower_limit="86.7" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Complete Cytogenic Response (CCyR)</title>
        <description>Time to CCyR is defined as the time from the date of randomization to the date of first documented CCyR</description>
        <time_frame>24 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Cytogenic Response (CCyR)</title>
          <description>Time to CCyR is defined as the time from the date of randomization to the date of first documented CCyR</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="5.8" upper_limit="10.9"/>
                    <measurement group_id="O2" value="5.7" lower_limit="5.6" upper_limit="5.7"/>
                    <measurement group_id="O3" value="5.7" lower_limit="5.7" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of CCyR</title>
        <description>Duration of CCyR is defined as the time from date of first documented CCyR to the earliest date of loss of CCyR.</description>
        <time_frame>up to 72 months</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of CCyR</title>
          <description>Duration of CCyR is defined as the time from date of first documented CCyR to the earliest date of loss of CCyR.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of duration CCyR</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of duration CCyR</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of duration CCyR</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-free survival is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring in the core or extension study, or during the follow-up period after discontinuation of core or extension study</description>
        <time_frame>approx. 11 years</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-free survival is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring in the core or extension study, or during the follow-up period after discontinuation of core or extension study</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median or CI of PFS</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median or CI of PFS</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median or CI of PFS</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival (EFS)</title>
        <description>Event-free survival is defined as the time from the date of randomization to the date of first occurrence of any of the following: death due to any cause (if death is the primary reason for discontinuation), progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR</description>
        <time_frame>approx. 11 years</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival (EFS)</title>
          <description>Event-free survival is defined as the time from the date of randomization to the date of first occurrence of any of the following: death due to any cause (if death is the primary reason for discontinuation), progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of EFS</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of EFS</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of EFS</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is defined as the time from the date of randomization to the date death. Up to 10 calendar years of follow up from the date when the last patient randomized received the first dose of study drug in all active treatment arms of adult patients with Ph+ CML CP.</description>
        <time_frame>approx. 11 years</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is defined as the time from the date of randomization to the date death. Up to 10 calendar years of follow up from the date when the last patient randomized received the first dose of study drug in all active treatment arms of adult patients with Ph+ CML CP.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of OS</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of OS</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of OS</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actual Dose-intensity</title>
        <description>Actual dose intensity is defined as total dose over time on treatment</description>
        <time_frame>approx. 11 years</time_frame>
        <population>Safety Set: Safety set contained 836 patients who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Actual Dose-intensity</title>
          <description>Actual dose intensity is defined as total dose over time on treatment</description>
          <population>Safety Set: Safety set contained 836 patients who received at least one dose of study medication.</population>
          <units>mg/day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400.0" lower_limit="206" upper_limit="800"/>
                    <measurement group_id="O2" value="591.1" lower_limit="186" upper_limit="699"/>
                    <measurement group_id="O3" value="758.9" lower_limit="232" upper_limit="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression to AP/BC</title>
        <description>Time to progression to AP/BC is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of CML related death.</description>
        <time_frame>approx. 11 years</time_frame>
        <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression to AP/BC</title>
          <description>Time to progression to AP/BC is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of CML related death.</description>
          <population>Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of TTP</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of TTP</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = not enough events to calculate median and CI of TTP</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Cmax</title>
        <description>Cmax is defined as the maximum serum concentration after dose</description>
        <time_frame>any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration</time_frame>
        <population>Global Full Pharmacokinetics (PK) set: Full-PK set contained 16 patients who received nilotinib. Full PK profile was meant for nilotinib arms only and included all patients with available Full PK profile at one visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O2">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Cmax</title>
          <description>Cmax is defined as the maximum serum concentration after dose</description>
          <population>Global Full Pharmacokinetics (PK) set: Full-PK set contained 16 patients who received nilotinib. Full PK profile was meant for nilotinib arms only and included all patients with available Full PK profile at one visit.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1555" lower_limit="1340" upper_limit="2300"/>
                    <measurement group_id="O2" value="1440" lower_limit="1002" upper_limit="2125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Cmin</title>
        <description>Cmin is defined as the minimum serum concentration after dose</description>
        <time_frame>any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration</time_frame>
        <population>Global Full Pharmacokinetics (PK) set: Full-PK set contained 16 patients who received nilotinib. Full PK profile was meant for nilotinib arms only and included all patients with available Full PK profile at one visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O2">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Cmin</title>
          <description>Cmin is defined as the minimum serum concentration after dose</description>
          <population>Global Full Pharmacokinetics (PK) set: Full-PK set contained 16 patients who received nilotinib. Full PK profile was meant for nilotinib arms only and included all patients with available Full PK profile at one visit.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1430" lower_limit="1250" upper_limit="1740"/>
                    <measurement group_id="O2" value="915" lower_limit="752" upper_limit="2080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Tmax</title>
        <description>Tmax is defined as the sampling time when maximum measured serum concentration occurs</description>
        <time_frame>any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration</time_frame>
        <population>Global Full Pharmacokinetics (PK) set: Full-PK set contained 16 patients who received nilotinib. Full PK profile was meant for nilotinib arms only and included all patients with available Full PK profile at one visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O2">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Tmax</title>
          <description>Tmax is defined as the sampling time when maximum measured serum concentration occurs</description>
          <population>Global Full Pharmacokinetics (PK) set: Full-PK set contained 16 patients who received nilotinib. Full PK profile was meant for nilotinib arms only and included all patients with available Full PK profile at one visit.</population>
          <units>hour (h)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" lower_limit="0.50" upper_limit="2.04"/>
                    <measurement group_id="O2" value="1.50" lower_limit="0.00" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: AUC0-last</title>
        <description>AUC0-last is defined as area under concentration-time curve from time zero to the last measurable sample, calculated by log-linear trapezoidal method</description>
        <time_frame>any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration</time_frame>
        <population>Global Full Pharmacokinetics (PK) set: Full-PK set contained 16 patients who received nilotinib. Full PK profile was meant for nilotinib arms only and included all patients with available Full PK profile at one visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O2">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: AUC0-last</title>
          <description>AUC0-last is defined as area under concentration-time curve from time zero to the last measurable sample, calculated by log-linear trapezoidal method</description>
          <population>Global Full Pharmacokinetics (PK) set: Full-PK set contained 16 patients who received nilotinib. Full PK profile was meant for nilotinib arms only and included all patients with available Full PK profile at one visit.</population>
          <units>h.ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14446" lower_limit="12806" upper_limit="17411"/>
                    <measurement group_id="O2" value="11689" lower_limit="7925" upper_limit="18678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</title>
        <description>Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count &lt;10 x 109/L, Platelet count &lt;450 x 109/L, Basophils &lt;5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes &lt; 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).</description>
        <time_frame>Overall for Extension study for approx. 10 years</time_frame>
        <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</title>
          <description>Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count &lt;10 x 109/L, Platelet count &lt;450 x 109/L, Basophils &lt;5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes &lt; 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).</description>
          <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="69.8" upper_limit="92.5"/>
                    <measurement group_id="O2" value="84.6" lower_limit="65.1" upper_limit="95.6"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</title>
        <description>Rate of CCyR is defined as the percentage of participants in complete cytogenetic response (CCyR). CcyR is defined as 0% of Ph+ metaphases in the bone marrow.</description>
        <time_frame>Overall for Extension study for approx. 10 years</time_frame>
        <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</title>
          <description>Rate of CCyR is defined as the percentage of participants in complete cytogenetic response (CCyR). CcyR is defined as 0% of Ph+ metaphases in the bone marrow.</description>
          <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="58.2" upper_limit="84.7"/>
                    <measurement group_id="O2" value="73.1" lower_limit="52.2" upper_limit="88.4"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</title>
        <description>Rate of MMR is defined as the percentage pf participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR))</description>
        <time_frame>Overall for Extension study for approx. 10 years</time_frame>
        <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</title>
          <description>Rate of MMR is defined as the percentage pf participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR))</description>
          <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" lower_limit="49.5" upper_limit="77.8"/>
                    <measurement group_id="O2" value="73.1" lower_limit="52.2" upper_limit="88.4"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</title>
        <description>Molecular response of &lt;=0.01% is defined as BCR-ABL ratio (%) on IS &lt;= 0.01% (corresponds to &gt;=4 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
        <time_frame>Overall for Extension study for approx. 10 years</time_frame>
        <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</title>
          <description>Molecular response of &lt;=0.01% is defined as BCR-ABL ratio (%) on IS &lt;= 0.01% (corresponds to &gt;=4 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
          <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" lower_limit="29.5" upper_limit="58.8"/>
                    <measurement group_id="O2" value="57.7" lower_limit="36.9" upper_limit="76.6"/>
                    <measurement group_id="O3" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</title>
        <description>Molecular response of &lt;=0.0032% is defined as BCR-ABL ratio (%) on IS &lt;= 0.0032% (corresponds to &gt;=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
        <time_frame>Overall for Extension study for approx. 10 years</time_frame>
        <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)</title>
          <description>Molecular response of &lt;=0.0032% is defined as BCR-ABL ratio (%) on IS &lt;= 0.0032% (corresponds to &gt;=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)</description>
          <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" lower_limit="22.2" upper_limit="50.5"/>
                    <measurement group_id="O2" value="38.5" lower_limit="20.2" upper_limit="59.4"/>
                    <measurement group_id="O3" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension)</title>
        <description>This is the percentage of patients with any emergent mutation on extension treatment. The mutation comprised of T315T, less sensitive to nilotinib, unknown and sensitive to nilotinib.</description>
        <time_frame>Overall for Extension study for approx. 10 years</time_frame>
        <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension)</title>
          <description>This is the percentage of patients with any emergent mutation on extension treatment. The mutation comprised of T315T, less sensitive to nilotinib, unknown and sensitive to nilotinib.</description>
          <population>Extension Set: The Extension set (ES) consisted of patients who received at least one dose of treatment in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                    <measurement group_id="O2" value="11.5"/>
                    <measurement group_id="O3" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>All Collected Deaths</title>
        <description>On treatment deaths were collected from first patient first visit up to 28 days after study treatment discontinuation (approx. 11 years). Patients with cancer were also followed up for overall survival until the end of the trial (to collect any deaths occurring more than 28 days after study drug discontinuation). In this study, one death was collected after randomization but before the participant received study drug.</description>
        <time_frame>From FPFV up to 28 days post treatment (approx. 11 years), From FPFV to LPLV (approx. 12 years)</time_frame>
        <population>Safety analysis set consisted of all patients who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 400 mg QD</title>
            <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
          </group>
          <group group_id="O2">
            <title>Nilotinb 300 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 400 mg BID</title>
            <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>All Collected Deaths</title>
          <description>On treatment deaths were collected from first patient first visit up to 28 days after study treatment discontinuation (approx. 11 years). Patients with cancer were also followed up for overall survival until the end of the trial (to collect any deaths occurring more than 28 days after study drug discontinuation). In this study, one death was collected after randomization but before the participant received study drug.</description>
          <population>Safety analysis set consisted of all patients who received at least one dose of study medication.</population>
          <units>deaths</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On-treatment deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event (AE) time frame: Adverse events were collected from first dose of study treatment until end of study treatment plus 28 days post treatment, up to maximum duration of approx. 11 years.</time_frame>
      <desc>Adverse Event (AE): Any sign or symptom that occurs during the study treatment plus 28 days post treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Imatinib 400 mg QD</title>
          <description>Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated</description>
        </group>
        <group group_id="E2">
          <title>Nilotinib 300 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
        <group group_id="E3">
          <title>Nilotinib 400 mg BID</title>
          <description>Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.</description>
        </group>
        <group group_id="E4">
          <title>All Patients</title>
          <description>All patients randomized in the study to all 3 arms and received at least one dose of study drug.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="334" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypoplastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Brugada syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cytogenetic abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Trisomy 8</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Faecal vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastric mucosa erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pancreatic fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peritoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Perihepatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cardiac valve replacement complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Incorrect dose administered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Kidney contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blast cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase MB increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cardioactive drug level increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Haematoma muscle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Spinal ligament ossification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Benign uterine neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blast cell crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blast crisis in myelogenous leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Chloroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Histiocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Leukaemic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Metastases to abdominal wall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pancreatic neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Paraproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Rosai-Dorfman syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Superficial spreading melanoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Basilar artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cerebellar stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cerebral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Demyelination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Essential tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Focal dyscognitive seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Miller Fisher syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Vertebral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Retained products of conception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Adnexa uteri pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Scrotal swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Mediastinal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="276" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="272" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="823" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="154" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="134" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="168" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="132" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="158" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="145" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="264" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="111" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="273" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="187" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="109" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="187" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="141" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="138" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="121" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="141" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="218" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="170" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="209" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="125" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="154" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="206" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="194" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="178" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="169" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="154" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="278" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="108" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="165" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="127" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="95" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="149" subjects_at_risk="836"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="307" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="128" subjects_at_risk="836"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

